Unexpected mechanisms of action for a cytokine receptor-blocking antibody.

Hercus, Timothy R; Broughton, Sophie E; Hardy, Matthew P; Nero, Tracy L; Wilson, Nicholas J; Parker, Michael W; Lopez, Angel F

Hercus, Timothy R; Broughton, Sophie E; Hardy, Matthew P; Nero, Tracy L; Wilson, Nicholas J; Parker, Michael W; Lopez, Angel F.

Afiliação

Hercus TR; The Centre for Cancer Biology; SA Pathology and the University of South Australia ; Adelaide, South Australia.
Broughton SE; Australian Cancer Research Foundation Rational Drug Discovery Centre; St. Vincent's Institute of Medical Research ; Fitzroy, Victoria.
Hardy MP; CSL Limited ; Parkville, Victoria.
Nero TL; Australian Cancer Research Foundation Rational Drug Discovery Centre; St. Vincent's Institute of Medical Research ; Fitzroy, Victoria.
Wilson NJ; CSL Limited ; Parkville, Victoria.
Parker MW; Australian Cancer Research Foundation Rational Drug Discovery Centre; St. Vincent's Institute of Medical Research; Fitzroy, Victoria; Department of Biochemistry and Molecular Biology; Bio21 Molecular Science and Biotechnology Institute; University of Melbourne; Parkville, Victoria, Australia.
Lopez AF; The Centre for Cancer Biology; SA Pathology and the University of South Australia ; Adelaide, South Australia.

Mol Cell Oncol ; 1(4): e969129, 2014.

Article em En | MEDLINE | ID: mdl-27308368

RESUMO

CSL362 is a humanized interleukin-3 (IL-3)-neutralizing monoclonal antibody with enhanced effector function that binds the α subunit of the IL-3 receptor (IL3Rα). The crystal structure of an IL3Rα:CSL362 complex shows that IL3Rα adopts "open" and "closed" conformations. CSL362 blocks IL-3 function through both IL3Rα conformations but via distinct and unexpected mechanisms.

Palavras-chave

antibodies; cancer; cytokine receptor; signaling

Texto completo

Imprimir

XML

PubMed Links

Buscar no Google

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2014 Tipo de documento: Article

Texto completo

Imprimir

XML

PubMed Links